Lancaster Laboratories’ launches new mycoplasma USP <63> assay; harmonizes with EP Guidelines

November 17, 2010

Lancaster Laboratories, a global leader in biological safety testing, has introduced a new cGMP compliant mycoplasma assay, harmonizing both United States Pharmacopeia (USP) Chapter <63> monograph and European Pharmacopoeia Chapter 2.6.7 guidelines.

With the USP’s recently published Chapter <63> Mycoplasma Tests, biopharmaceutical companies performing mycoplasma testing need to comply with this new guideline, effective October 1, 2010. Chapter <63> was intended to bring requirements in the U.S. closer to those outlined in the EP and to further harmonize mycoplasma testing by bringing greater alignment in the monographs.

Mycoplasma contamination of cell culture represents a significant issue in the development and production of biologics. Mycoplasma contamination events can lead to altered physiological properties of cells, leading to reduced or altered cellular products and perhaps unsafe biopharmaceuticals. Thus, testing for the presence of mycoplasma contamination in development and manufacturing is a requirement by the worldwide regulatory agencies, including the United States, Europe and Japan. Guidance for this testing is provided in the FDA 1993 Points to Consider (PTC), European Pharmacopoeia Chapter 2.6.7 Mycoplasmas, and the Japanese Pharmacopeia XV,14. Mycoplasma Testing.  

“By offering validated assays performed in compliance with FDA, PTC, EP and USP, we are ensuring compliance for mycoplasma screening of cell lines and biological products for our global customers.” says Dr. Jeri Ann Boose, Lancaster Laboratories’ director of biopharmaceutical services.

Features of Lancaster Laboratories Mycoplasma testing program include:

  • Fully traceable, characterized and qualified positive control strains
  • Formalized analyst training program, including required proficiency assessments using blind samples
  • Limited access laboratories that are pressure-controlled, HEPA-filtered, and operate on independent air handling systems to prevent cross contamination
  • Separate laboratories for testing of client test articles and handling of positive control strains, including a unidirectional workflow that ensures handling of test articles prior to manipulating positive controls on each working day
  • Assays performed in strict compliance with cGMPs
  • Mycoplasmastasis testing to qualify each assay for each test article
  • Support for mycoplasma clearance studies, including consultation and study design
  • Access to Lancaster Labs’ proprietary LabAccess system, allowing 24/7 easy access to study information, final reports and actual raw study data


Founded in 1961, Lancaster Laboratories is the global leader in pharmaceutical and biopharmaceutical laboratory services, providing innovative and timely scientific solutions that enable customers to better manage the drug development process.  Visit lancasterlabspharm.com and discover why customers rank Lancaster Laboratories #1.

Lancaster Laboratories is part of Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.